Marina Pedemonte

Gene expression profiling in the early phases of DMD: a constant molecular signature characterizes DMD muscle from early postnatal life throughout disease progression

Mario Pescatori, Aldobrando Broccolini, Carlo Minetti et al. · The FASEB Journal · 2007 · 244 citations

Muscle Function, Engineering, Genetics +17

Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial

Eugenio Mercuri, Francesco Muntoni, Giovanni Baranello et al. · The Lancet Neurology · 2021 · 237 citations

Gene Therapies, Clinical Trials, Neurology +2

Transgenic overexpression of caveolin-3 in skeletal muscle fibers induces a Duchenne-like muscular dystrophy phenotype

Ferruccio Galbiati, Daniela Volonté, Jeffrey B. Chu et al. · Proceedings of the National Academy of Sciences · 2000 · 148 citations

Nusinersen in type 1 spinal muscular atrophy: Twelve‐month real‐world data

Marika Pane, Giorgia Coratti, Valeria Sansone et al. · Annals of Neurology · 2019 · 120 citations

Apoptotic myonuclei in human Duchenne muscular dystrophy.

Marco Sandri, Carlo Minetti, Marina Pedemonte et al. · PubMed · 1998 · 113 citations